Skip to content

Search Results

No Matching Results

    Recently Viewed


      HomeLatest news5 facts about Johnson & Johnson’s investigational Janssen COVID-19 vaccine candidate
      A potential COVID-19 vaccine

      5 facts about Johnson & Johnson’s investigational Janssen COVID-19 vaccine candidate

      With its global Phase 3 clinical trial now fully enrolled with approximately 45,000 adult participants, we share the most up-to-date information about the single-dose investigational vaccine candidate.

      Share Article
      share to

      In January 2020, just as SARS-CoV-2, which causes COVID-19, began to spread around the globe, the Janssen Pharmaceutical Companies of Johnson & Johnson started researching potential vaccine candidates.

      A close-up view of SARS-CoV-2

      A close-up view of SARS-CoV-2

      Three months later, scientists at the company announced a lead vaccine candidate in development at Janssen and its plans to put it into a Phase 1/2a human clinical trial no later than September 2020—a timeline that, in June, the company announced it would shorten.

      In July, data published in Nature showed that Janssen’s investigational vaccine elicited an immune response against SARS-CoV-2 in a preclinical, nonhuman study.

      Based on the positive data from this preclinical study, which was conducted in collaboration with researchers from Beth Israel Deaconess Medical Center, first-in-human trials of the potential vaccine began in July.*

      “We were excited to see these preclinical data because they showed our COVID-19 vaccine candidate generated a strong antibody response and provided protection with a single dose,” says Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer, Johnson & Johnson. “The findings give us confidence as we progress our vaccine development and upscale manufacturing in parallel.”

      On September 23, Johnson & Johnson announced it was initiating a multi-country Phase 3 clinical trial to further evaluate the safety and efficacy of Janssen’s COVID-19 vaccine candidate.**

      In December 2020, the Phase 3 trial, known as ENSEMBLE, reached full enrollment with roughly 45,000 adult participants.

      Johnson & Johnson is deploying the full strength of its science, scale and expertise to help fight the pandemic as COVID-19 continues to affect people and communities across the world—according to the World Health Organization, as of this month, global cases have now surpassed 80 million.

      Read on to learn the latest facts about Janssen’s investigational COVID-19 vaccine candidate.


      The company launched Phase 1/2a first-in-human trials in July

      Gloved hands with vaccine syringe

      On June 10, Johnson & Johnson announced it would begin early-stage testing of Janssen’s vaccine candidate in humans in the second half of July.

      The randomized, double-blind, placebo-controlled Phase 1/2a trial—which means neither participants nor investigators or study staff know who is getting a placebo and who is getting the vaccine candidate—aims to evaluate a few things: the safety of the potential vaccine; expected reactions to vaccination, such as swelling or soreness at the injection site; and immune responses to the potential vaccine.

      The trial also explores multiple vaccination schedules and dose levels for the potential vaccine.


      1,045 people participated in the Phase 1/2a trials

      Healthy participants in Belgium and the U.S. between the ages of 18 and 55, as well as those 65+, were assigned to receive the vaccine candidate or a placebo.

      Johnson & Johnson identified clinical study sites in cities that have underserved and underrepresented populations and partnered with organizations to proactively identify and include diverse patient populations. The company also worked to mitigate hurdles to participation at various sites, such as transportation and childcare, to ensure a diverse group of study volunteers were recruited.

      Plans were also underway for a Phase 1 study in Japan, as well as a Phase 2 study in the Netherlands, Spain and Germany.


      Johnson & Johnson initiated a Phase 3 global clinical trial in September and reached full enrollment in December


      Johnson & Johnson’s investigational Janssen COVID-19 vaccine candidate

      Based on positive interim results from a Phase 1/2a trial, which demonstrated that Janssen’s investigational vaccine candidate’s safety profile and ability to evoke an immune response after a single vaccination were supportive of further development, and discussions with regulators, the company launched a Phase 3 pivotal trial in September.

      This randomized, double-blind, placebo-controlled clinical trial, called ENSEMBLE, is designed to evaluate the safety and efficacy of a single vaccine dose versus a placebo in preventing COVID-19 in a large group of participants, with results to be evaluated by regulatory authorities.

      In December 2020, the trial reached full enrollment with roughly 45,000 adult participants.

      In order to ensure that those who have been disproportionately impacted by the pandemic were represented, such as Black and Latinx communities, effort was put toward ensuring all races, ethnicities, ages and medical conditions are reflected in the trial.

      In parallel, the ENSEMBLE 2 trial, which the company is currently recruiting for, will give participants two doses of the vaccine candidate, spaced two months apart, to see if a second dose might provide greater, or longer, protection.***


      Janssen plans to produce more than 1 billion doses of a potential vaccine to be distributed globally through 2021

      Provided that the investigational vaccine proves to be safe and effective, the company aims to manufacture more than one billion doses to be distributed globally through 2021.

      As part of that goal, in August 2020, Johnson & Johnson announced that Janssen had entered into an agreement with the U.S. government to manufacture and deliver 100 million doses of the investigational vaccine in the U.S., provided that it is approved or receives Emergency Use Authorization by the U.S. Food and Drug Administration.

      These efforts—along with research and development—are spurred by an expanded collaboration between Janssen and the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health & Human Services.

      Janssen is using the same technology that it has used in the development of its Ebola vaccine and investigational HIV, RSV and Zika vaccine candidates, which involves using an inactivated common cold virus that’s not replicating.


      The company is also scaling up manufacturing

      An employee working on a manufacturing line

      The investigational vaccines will be produced at Janssen’s facility in Leiden, the Netherlands. In April the company also announced manufacturing partnerships in the U.S., and, recently, one in Italy, with more plants to potentially be added in other countries.

      This expanded production capability aims to enable the company to rapidly scale up to produce and provide more than 1 billion doses to people around the world.

      The company’s potential vaccine would be able to be distributed through standard, reliable channels around the world, and it would not require special transport or infrastructure to reach populations in need.

      *This project has been funded in whole or in part with Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, under Other Transaction Agreement HHSO100201700018C.

      ** This trial is being initiated in collaboration with the Assistant Secretary for Preparedness and Response (ASPR), the Biomedical Advanced Research and Development Authority (BARDA) and the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).

      *** This story was updated on January 4, 2021

      More from Johnson & Johnson

      Meet a nurse who leads clinical trials to find innovative cancer therapies

      Melissa Martinez is a clinical scientist within Johnson & Johnson’s Interventional Oncology R&D group. Not only is she helping to develop lifesaving treatments, she’s redefining what it means to pursue a career in nursing.

      What’s the difference between IBS and IBD?

      These GI conditions sound similar, and they also share some symptoms. But IBS and IBD are distinct disorders—especially when it comes to treatment and the risk of complications.

      What is IL-23?

      This pro-inflammatory protein is the target of potential Johnson & Johnson medications that could help treat autoimmune conditions such as psoriasis, inflammatory bowel disease and rheumatoid arthritis.
      You are now leaving The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.